ANZCTR search results

This phase 1 study will aim to predict a response to radiotherapy treatment in prostate cancer patients. Who is it for? You may be eligible to join this study if you are aged 18 years or above, and have been diagnosed with prostate cancer and have been recommended radiotherapy treatment. Study details Participants will undergo normal radiotherapy treatment with the addition of up to 5 MRI scans prior to and following radiotherapy treatment, up to 2 PSMA PET scans prior to and following radiotherapy treatment and up to 5 pathology blood tests prior to and following radiotherapy treatment. This study will determine the pre-treatment clinical and radiographic predictors of local recurrence in prostate cancer patients treated with radiotherapy.

This research study is designed to assess whether a special MRI scan can accurately predict the extent of cancer spread in the abdominal cavity in advanced ovarian cancer. Who is it for? You may be eligible for this study if you have a diagnosis of metastatic ovarian cancer and are aged over 18 years old. Study details All participants in this study will undergo an MRI scan no longer than 2 weeks prior to their routine diagnostic laparoscopy. This scan will take approximately 60 minutes. Participants will also give informed consent for access to their medical records. It is hoped this research might demonstrate that MRI scans can replace surgery when assessing the spread of advanced ovarian cancer in the abdominal cavity.

The purpose of the study is to investigate whether a permanent implant of a new spinal cord stimulation system, which uses automatic control, is safe and effective at treating chronic pain of the upper limbs and/or neck. The Stimulator System being investigated in the study is similar to currently available stimulators and treats chronic pain conditions in a similar way. The differences between participating in the study and receiving a currently available stimulator system is that: the System has technology to automatically control the strength of stimulation that you will feel; This type of automatic control stimulation has been studied previously in Australia and the U.S. for lower-back and leg pain. A total of 163 participants have been implanted with the Evoke system so far. All the surgical procedures and medical care in this study are similar to the currently available stimulators. This study is the first time the Evoke system is tested for upper-limb and/or neck pain. The stimulators that will be used during the study (external trial stimulator and implantable stimulator) are investigational devices that are as yet unapproved by the Department of Health, Therapeutic Goods Administration (TGA).

This trial aims to determine the effects of short-term intranasal oxytocin intervention on emotional processing in individuals diagnosed with Frontotemporal Dementia . We further wish to evaluate whether administration of oxytocin has an effect on carer-burden using standardised questionnaires to capture changes in patient-carer relationships. Who is it for? Patients between the ages of 40 to 75 years, who have been diagnosed with behavioural variant frontotemporal dementia, semantic dementia or progressive non-fluent aphasia, and have a carer who will be able to live with them for the duration of the study are eligible to participate. Study details Patients who have previously been recruited by the Frontier Research Clinic for the 'Clinical Assessment for Ageing and Neurodegeneration Research' study will be contacted to participate in this four-week clinical trial using oxytocin nasal spray. Patients will undergo clinical and neuropsychological assessments at their initial visit, followed by assessments of emotion, cognition, carer-burden and blood sampling at further visits. Patients will be randomised to receive either placebo or oxytocin for one-week, then be off any intervention for one week followed by the counter-intervention for a one-week period. Experimental tasks and clinical assessments will be performed at the Brain and Mind Centre on appropriate visit days and study compliance will be monitored using a drug diary and help from the caregiver.

The NINJA clinical trial aims to compare two emerging schedules of radiotherapy in the treatment of prostate cancer. Who is it for? You may be eligible for this study if you are an adult male over the age of 18 who has been diagnosed with intermediate or high risk prostate cancer . Study details Participants will be randomly assigned to one of two radiotherapy schedules as part of this study. In schedule 1 (called Sterotactic Body Radiotherapy) participants will receive 5 radiotherapy treatments over 2 weeks and in schedule 2 (called Virtual High Dose Rate Boost) participants will receive Sterotactic Body Radiotherapy delivered in 2 treatments over 1 week followed by 12 treatments of conventional external beam radiotherapy over 2 and a half weeks. A blood test will be collected at the initial assessment, 6 weeks after radiotherapy and 6 monthly for a period of 5 years. Questionnaires will completed at the initial assessment, 6 weeks after radiotherapy and at 2 and 5 years. It is hoped that this research will potentially improve the accuracy and quality of radiotherapy treatment in prostate cancer.

This clinical trial aims to determine why the positive findings in lung function and exercise tolerance occur following bronchoscopic lung volume reduction therapy of Chronic Obstructive Pulmonary Disease (COPD). It is thought that these improvements are a result of changes in lung, heart, and vasculature physiology following this treatment. This trial will investigate all three areas, using a combination of Cardiopulmonary Exercise Testing (CPET), Echocardiogram, Cardiac Magentic Resonance Imaging, Nuclear Medicine SPECT scanning, and measurement of blood serum biomarkers. The results of this study may assist in the future identification and selection of patients for this procedure, thereby improving their overall care and management.

BTX 1308 contains the active pharmaceutical ingredient, cannabidiol in a topical liquid formulation, and is being developed for the treatment of psoriasis vulgaris by Botanix Pharmaceuticals Limited. CBD is a member of a broader family of compounds known as cannabinoids, a class of compounds originally derived from the cannabis sativa plant. CBD is chemically synthesized under Good Manufacture Practices (GMP) for use in this study.The objective of this study is to assess preliminary safety, tolerability, and activity of various formulations and concentrations of BTX 1308 in subjects with mild to moderate, stable, plaque-type psoriasis. This will be a single-center, vehicle and comparator-controlled, evaluator-blinded study in volunteers aged 18 years and over. Participants will receive 4 treatments, across up to 3 comparable psoriasis plaques. BTX 1308 – 1 5% BTX 1308 – 3 20% BTX 1308 Vehicle Approved psoriasis product – Betnovate® (betamethasone valerate) Ointment 0.1% Safety and cutaneous tolerability will be assessed by the collection and review of AEs and application site review, laboratory parameters throughout the duration of the trial. Efficacy assessments will include measurement of the thickness of the psoriatic inflammatory infiltrate using sonography. Photography of the treated area will be conducted for all participants. Participants will remain in follow up until 19 days following the first application of investigational product.

This study is investigating whether the presence of therapy dogs in speech pathology sessions with preschool children has a positive impact on language and social communication, It is hypothesised that the use of therapy dogs will lead to further gains in these children's language development, participation and engagement with therapy sessions.

This project is investigating how a home-based family caregiver directed music intervention impacts the behavioural and psychological symptoms of dementia, the levels of depression in person living with dementia and their family caregiver, and their quality of life. It is part of larger international study involving European investigators. The project will study the impact of music on wellbeing for 198 older Australians (99 dyads) over a 6-month period, with a total sample size of 495 dyads across the 5 countries. Each dyad will be randomly assigned to either a music intervention, a reading intervention (active control) or standard care. Over the 6-month period, we will be collecting a range of data that will help us understand whether music has or has an effect on participants' mood, quality of life, and symptoms of dementia. Moreover, we will be asking carers to complete measures about their own wellbeing to help us understand the impact of the music intervention has on caregivers' wellbeing and burden.

The purpose of this study is to assess the feasibility and acceptability of a pharmacist and nurse-led intervention to help management of medication in people taking ibrutinib. Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with chronic lymphocytic leukaemia, small lymphocytic lymphoma, mantle cell lymphoma or walenstrom’s macroglobulinaemia and are scheduled to commence ibrutinib as part of your usual care. Study details Participants will be randomly allocated to one of two groups. One group will receive usual care including standard medication management. The other group will receive a face-to-face consultation with a pharmacist to discuss their medication, and complete five phone calls with a nurse over 12 weeks to assist with taking medication as prescribed by their doctor. Participants in the second group will also use a phone app that will provide daily medication reminders, and access to advice on how to manage any side-effects. All participants will also complete questionnaires relating to their health and complete routine blood tests. It is hoped that this research will help provide an effective way of managing medications during cancer treatment.